Key result
Private sector drug-eluting stent prices exceed public system costs, with price dispersion reaching ~177%.
Why the study?
Lack of price transparency for high-cost medical devices like drug-eluting coronary stents may create barriers to access, motivating an evaluation of prices and regional heterogeneity across Brazilian public and private health sectors.
How do drug-eluting coronary stent prices and regional price dispersion compare between the private Supplementary Health sector and the public Unified Health System (SUS) in Brazil from 2019 to 2024?
Observational (n=49,796)
Yes
How do drug-eluting coronary stent prices and regional price dispersion compare between the private Supplementary Health sector and the public Unified Health System (SUS) in Brazil from 2019 to 2024?
Answers are grounded in this paper and cite their sources.
Drug-eluting coronary stent prices in Brazil are substantially higher and more variable in the private sector than in the public health system, with marked regional disparities that highlight the need for improved economic regulation and price transparency.
Introduction: High-cost medical devices, such as drug-eluting coronary stents (DES), may create barriers to access when price information lacks transparency. Objective: To describe DES prices from 2019 to 2024, compare the Brazilian Unified Health System (SUS) with the private health sector (Supplementary Health – SH), and assess regional heterogeneity. Method: This retrospective observational study used data from the Brazilian National Supplementary Health Agency (ANS) and the National Implant Registry (RNI/Anvisa), the latter used as a sample of procedures performed within SUS. The analytical unit was the Anvisa registration number, precluding comparisons between specific device models. The databases were cleaned and adjusted for inflation using the Brazilian Extended National Consumer Price Index (IPCA). Comparisons across states and geographic regions were performed using nonparametric methods, and prices were summarized using medians and interquartile ranges, as well as means and standard deviations. Results: In the SH database, 40,649 records from 24 states remained after data processing. In the RNI/SUS database, 9,147 valid observations from 11 states were analyzed. SH showed higher prices and greater price dispersion, with differences of up to 177% for the same Anvisa registration considering only the first and third quartiles (Q1–Q3). Regional heterogeneity was observed in both datasets, with the highest median prices in the North and Northeast regions. Conclusions: In the sample analyzed, DES prices were higher and more dispersed in SH than in the RNI/SUS, with important regional differences. Greater integration of databases, systematic data collection, and improvements in economic regulation may contribute to increased efficiency and equity.
No takes yet. Share an insight, caveat, or question.
Teixeira et al. (2026) conducted an observational in Patients undergoing coronary artery stenting with drug-eluting stents (n=49,796). Private health sector (Supplementary Health - SH) drug-eluting coronary stent pricing vs. Brazilian Unified Health System (SUS / RNI/Anvisa) drug-eluting coronary stent pricing was evaluated on Inflation-adjusted drug-eluting coronary stent prices and price dispersion across health sectors and geographic regions. Supplementary Health sector drug-eluting stent prices were higher and more dispersed than in SUS, with Q1-Q3 differences up to 177% for the same Anvisa registration.
Synapse has enriched 10 related papers. Consider them for comparative context: